Feature|Articles|November 19, 2026

Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say

Fact checked by: Laura Joszt, MA
Listen
0:00 / 0:00

Key Takeaways

  • Workflow gaps, not assay cost, most often drive missed screening, as current performance measures and templated documentation emphasize guideline-directed medical therapy rather than iron metrics.
  • Lack of accountability for abnormal iron studies discourages ordering, since downstream responsibility for arranging IV repletion and monitoring is often unclear across cardiology and primary care.
SHOW MORE

Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

Iron deficiency screening in heart failure (HF) is inexpensive and guideline-endorsed, yet faculty say patients still slip through gaps in ownership, workflow, and reimbursement, and pharmacist-led, electronic health record (EHR)-driven processes are emerging as practical fixes.

Multidisciplinary faculty shared how their organizations are closing those gaps at The American Journal of Managed Care®’s Population Health Roundtable in Raleigh-Durham, North Carolina, on October 15, 2026. The panel of pharmacists, nephrologists, advanced practice clinicians, and a public health physician was led by a moderator.

Why Do Screened Patients Still Go Untreated?

Iron deficiency affects roughly half of patients with HF, whether or not they have anemia, and iron studies can be added to routine blood draws. Faculty said the problem is workflow, not cost.

"Until this gets incorporated in that same workflow, it just goes completely missed," said Glenn Herrington, PharmD, FACC, FHFSA, BCCP, CPP, of Novant Health Heart & Vascular Institute, noting that performance measures and smart phrases center on guideline-directed medical therapy.

Participants

  • Janna Beavers, PharmD, BCCP, CPP, FHFSA, WakeMed Heart & Vascular Physicians
  • Benjamin Catanese, MD, Duke University School of Medicine
  • Daniel Edmonston, MD, Duke University School of Medicine
  • Tanaya Foster, PA, WakeMed Health & Hospitals
  • Monique Godfrey, PharmD, BCCP, Duke University Hospital
  • Glenn Herrington, PharmD, FACC, FHFSA, BCCP, CPP, Novant Health Heart & Vascular Institute
  • Oksana Kamneva, PharmD, BCCP, BCCCP, CPP, Duke University Health System
  • Brian Klausner, MD, WakeMed Health & Hospitals

Ownership was the other recurring barrier. "General cardiology does not want me to order the iron studies because they don’t want to know if it’s low because they have to fix it," stated a clinical pharmacist practitioner.

Brian Klausner, MD, of WakeMed Health & Hospitals, added that primary care clinicians are unlikely to fill the gap; the accountable care organization he led once tracked 38 quality measures, and iron deficiency was not one of them.

Where Should Iron Repletion Start?

Faculty generally favored starting in the hospital, where daily laboratory tests and a captive care team make screening easier, and patients avoid travel and prior authorization. "Start the process inpatient, even if you aren’t able to initiate the treatment there, but you definitely have to have a plan for that transition and handoff to your outpatient side because this isn’t one and done," said Daniel Edmonston, MD, of Duke University School of Medicine.

Outpatient access is harder. Tanaya Foster, PA, of WakeMed Health & Hospitals, said her clinic stopped infusing patients after learning the hospital was not being reimbursed, which pushed patients to a hematology referral. Oksana Kamneva, PharmD, BCCP, BCCCP, CPP, of Duke University Health System, said coverage dictates the product. "It’s 100% payer-based. We don’t have ferric carboxymaltose at Duke as a formulary agent, even at our infusion clinics," she said. Klausner said poor reimbursement, including doses that do not add to a diagnosis-related group payment, is the “elephant in the room” behind clinical inertia.

Follow-up after repletion was a shared blind spot. "I think the biggest thing is losing track of these patients. Once they get repleted in the hospital, I honestly don’t think about it again," Foster said. Kamneva said her team adds a note to patients’ graduation documentation to prompt reconsultation when patient assistance expires.

Which Pharmacist-Led Models Are Working?

Several programs shift intravenous (IV) iron work from prescribers to pharmacists. Monique Godfrey, PharmD, BCCP, of Duke University Hospital, said a pharmacy handoff tool pulls in iron laboratory results and includes a checkbox so they are not skipped.

"One implementation we have is the heart failure dashboard that at least our cardiology group uses that pulls in the iron labs," she said. Kamneva added that Duke’s quality dashboard now reports iron screening quarterly.

One panelist described an automated order that refers patients to a pharmacist-led HF clinic within 7 days of discharge. The pharmacist then screens, follows up on laboratory results, arranges infusion, and handles prior authorization. Another panelist, a pharmacist, argued for formalizing the role. "There’s no reason we can’t have pharmacists to dose IV iron and have that as part of a heart failure admission order set," the panelist said, comparing it with pharmacist dosing of vancomycin and warfarin.

When system-wide change stalls, Herrington said, start locally. "You have to start somewhere, and it’ll be different at each of our institutions," he said.

What Did Faculty Take Away?

Participants agreed that no single fix will work. Common themes were naming an owner for abnormal results, building screening into admission workflows, using pharmacists to close ordering and prior authorization gaps, and tracking patients after the first infusion. Herrington said explaining that treatment can make patients feel better helps in counseling, and Klausner said emerging data on fewer hospitalizations strengthen the value-based argument for treating the sickest patients. Edmonston called for more outpatient trials to define follow-up and laboratory timing.


Related to this article